Athyrium Capital Management, LP

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 12, 2024), Athyrium Capital Management, LP reported 2 stock positions worth $8.7 million. Its top holding was Biora Therapeutics at 63.1% of the portfolio, followed by Puma Biotechnology (PBYI, 36.9%). Its holdings were unchanged from Q2 2024.

Most Recent 13F
Q3 2024
Location
New York, NY
CIK
0001728001
Portfolio Value
$8.7M (Q3 2024)
SEC Filing
0001123292-24-000336 ↗ filed Nov 12, 2024

Holdings Value

0$5.0M$10.0M$15.0M$20.0M Q1 2024: $18.7M Q1 2024 Q2 2024: $11.3M Q2 2024 Q3 2024: $8.7M $8.7M Q3 2024

Holdings 2 stocks · $8.7M
BIORA THERAPEUTICS INC 63.12% 10,929,762 $5.5M No change
PBYI Puma Biotechnology Inc. 36.88% 1,256,411 $3.2M No change

Portfolio Sells Q2 2024 → Q3 2024
None this quarter.

Portfolio Buys Q2 2024 → Q3 2024
None this quarter.

Notes & Other Activity Q2 2024 → Q3 2024
COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) NOTE 1.500% 4/1 · principal Sold out 30,000,000 $22.2Mbefore exit

Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2024 2$8.7MBIORA THERAPEUTICS INC, PBYI
Q2 2024 2$11.3MBIORA THERAPEUTICS INC, PBYI
Q1 2024 2$18.7MBIORA THERAPEUTICS INC, PBYI